View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 29, 2020

MGC receives second approval for Covid-19 trial in Israel

MGC Pharmaceuticals has received a second human research ethics committee approval in Israel to conduct a clinical trial of natural anti-infective based product ArtemiC in patients with Covid-19.

MGC Pharmaceuticals has received a second human research ethics committee approval in Israel to conduct a clinical trial of natural anti-infective based product ArtemiC in patients with Covid-19.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The approval was provided by the Hillel Yaffe Hospital, while the first approval was from Nazareth Hospital EMMS.

Considered a food supplement, ArtemiC is designed to help address viral infections with inflammatory complications.

The new double-blind, placebo controlled, Phase II trial will assess the safety and efficacy of the drug in Covid-19 patients.

It is expected to start in the coming weeks and will be completed in September this year, with results expected in October. The trial will enrol a total of 50 patients across two sites.

MGC Pharmaceuticals said in a statement: “The trial will evaluate the safety and efficacy of the product, and determine the claims which the product will be able to be sold as a food supplement. Importantly, MGC will own the intellectual property generated from the trial.

“The results from the trial will determine the valid claims that can be made in relation to the product, provide data points for future trials and will be material to the commercial discussions the company is currently undertaking with respect to potential supply and sale agreements of the product in the short term.”

The second site is intended to support the previous approval by offering wider statistical data to help in deciding on further testing for potential marketing authorisation approval.

MGC added that available scientific data on Artemisinin and Curcumin properties supports testing of ArtemiC in Covid-19 patients.

The company will also carry out research, manufacture and packaging for commercial orders from its operational facilities in Europe. It also has the approvals to start commercial production.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena